David Gindelberger

Dr. David Gindelberger serves as the Chief Scientific Officer of Apertus Pharmaceuticals where he leads the API research and commercialization efforts. David has deep expertise in the manufacturing and regulatory aspects of regulated API’s including over 18 years of research, manufacturing, and management experience in the pharmaceutical industry. He has most recently worked as a Principal Scientist for Mallinckrodt, the controlled substance manufacturing division of Covidien.

David also has prior entrepreneurial experience, having started a successful CMO focusing on the synthesis of organic compounds which he managed as President for four years. David established wet lab space including bench, hood, and glovebox installations, and analytical capabilities including a 300MHz Bruker NMR spectrometer. While running the CMO David initiated ongoing customer relationships with a number of entities including Sigma Aldrich, ExxonMobile, Umicore, and TCI Americas.

Previously, David was a Director of New Product Development at the Cal Tech-based start-up Materia. At Materia he focused on the commercialization of Robert Grubbs’ ruthenium olefin metathesis catalysts, and efforts to use this technology in pharmaceutical production. He has also worked as a Quality Manager at KMCO, the largest toll processor in the United States, and was a Senior Research Scientist for Exxon early in his career. David has a total of 17 patents and four pending applications spanning a wide variety of disciplines, including controlled substance and catalyst manufacturing.

David received his Ph.D. (Organometallic Chemistry) from the University of California, Berkeley, and his Bachelors (Chemistry) from Purdue University.